Literature DB >> 25617910

Neuropsychological short assessment of disease- and treatment-related intelligence deficits in children with brain tumours.

Holger Ottensmeier1, Bernhard Zimolong2, Johannes E Wolff3, Jochen Ehrich4, Niels Galley5, Katja von Hoff6, Joachim Kuehl7, Stefan Rutkowski6.   

Abstract

OBJECTIVE: The Wuerzburger Psychologische Kurz-Diagnostik (WUEP-KD) is a short screening battery for cognitive deficits in children with brain tumour. We report on its psychometric quality and testing efficiency.
MATERIAL AND METHODS: WUEP-KD was founded on Cattell-Horn-Carroll (CHC) framework of cognitive abilities. We assessed the construct validity of the short battery by conducting factor analysis and the concurrent validity by multiple linear regressions with Kaufman Assessment Battery for Children (K-ABC). The concurrent validity was explored by multiple linear regressions with Wechsler Intelligence Scale for Children (WISC). The discriminant validity was examined by a reanalysis of harmful effects of brain tumour treatments in a medulloblastoma cohort.
RESULTS: The construct validity assessment revealed three neuropsychological domains: cognitive operations, executive abilities, and psychomotor abilities. The retest reliabilities for individual testing and the convergent coefficients of the WUEP-KD with K-ABC and WISC yielded satisfactory results. The cognitive effects of different treatment modalities in the medulloblastoma cohort matched exactly previously reported data on the decline of general intelligence scores and delivered the details for the harmful effects. An in-depth analysis based on Hedges' g effect sizes confirmed specific harmful late effects on all abilities of cognitive operations, on the executive ability of perceptual speed and on psychomotor ability of movement steadiness.
CONCLUSION: WUEP-KD is a valid and efficient short test instrument, which may be especially useful in larger cohorts, multicenter settings or if patients do not tolerate longer tests. Due to its foundation on the CHC framework, our findings provide a rationale to create a common data set along with scores from other factor-based tests in international studies.
Copyright © 2015 European Paediatric Neurology Society. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Brain tumor; CHC framework; Cognitive ability; Cognitive deficits; Screening battery; Validity

Mesh:

Year:  2015        PMID: 25617910     DOI: 10.1016/j.ejpn.2014.12.019

Source DB:  PubMed          Journal:  Eur J Paediatr Neurol        ISSN: 1090-3798            Impact factor:   3.140


  4 in total

1.  Parent-reported cognitive function is associated with leukoencephalopathy in children with brain tumors.

Authors:  Jin-Shei Lai; Corey Bregman; Frank Zelko; Cindy Nowinski; David Cella; Jennifer J Beaumont; Stewart Goldman
Journal:  Qual Life Res       Date:  2017-04-26       Impact factor: 4.147

2.  Screening for cognitive deficits in 8 to 14-year old children with cerebellar tumors using self-report measures of executive and behavioral functioning and health-related quality of life.

Authors:  Kim S Bull; Christina Liossi; Janet L Peacock; Ho Ming Yuen; Colin R Kennedy
Journal:  Neuro Oncol       Date:  2015-07-22       Impact factor: 12.300

3.  Long-term cognitive deficits in pediatric low-grade glioma (LGG) survivors reflect pretreatment conditions-report from the German LGG studies.

Authors:  Thomas Traunwieser; Daniela Kandels; Franz Pauls; Torsten Pietsch; Monika Warmuth-Metz; Brigitte Bison; Juergen Krauss; Rolf-Dieter Kortmann; Beate Timmermann; Ulrich-Wilhelm Thomale; Peggy Luettich; Anne Neumann-Holbeck; Tanja Tischler; Pablo Hernáiz Driever; Olaf Witt; Astrid K Gnekow
Journal:  Neurooncol Adv       Date:  2020-08-08

4.  Treatment of children under 4 years of age with medulloblastoma and ependymoma in the HIT2000/HIT-REZ 2005 trials: Neuropsychological outcome 5 years after treatment.

Authors:  Holger Ottensmeier; Paul G Schlegel; Matthias Eyrich; Johannes E Wolff; Björn-Ole Juhnke; Katja von Hoff; Stefanie Frahsek; Rene Schmidt; Andreas Faldum; Gudrun Fleischhack; Andre von Bueren; Carsten Friedrich; Anika Resch; Monika Warmuth-Metz; Jürgen Krauss; Rolf D Kortmann; Udo Bode; Joachim Kühl; Stefan Rutkowski
Journal:  PLoS One       Date:  2020-01-23       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.